Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2022-04-20 AGM Information
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and contains detailed information about the upcoming AGM of Immunotech Biopharm Ltd, including the date, location, agenda items such as adoption of audited financial statements, re-election of directors, authorization of mandates for share issuance and repurchase, and other procedural details. It is a notice announcing the AGM and the business to be transacted, not the actual AGM materials or minutes. The document is over 11,000 characters, indicating it is a full notice rather than a brief announcement. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices related to it. It is not an Annual Report (10-K) or any other financial report, nor is it a voting result or proxy solicitation. Therefore, the correct classification is AGM Information (AGM-R).
2022-04-20 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular from Immunotech Biopharm Ltd dated 21 April 2022, containing detailed information about the upcoming Annual General Meeting (AGM) scheduled for 20 May 2022. It includes proposed re-election of retiring directors, proposed granting of general mandates to issue and repurchase shares, and the notice of the AGM itself. The document contains definitions, a letter from the board, details of directors proposed for re-election, explanatory statements on share repurchase mandates, and the AGM notice. This type of document is typically classified as AGM Information (AGM-R) because it provides materials and information related to the AGM, including resolutions to be considered and proxy arrangements. It is not a report of voting results, nor is it a financial report or earnings release. The length and content confirm it is a full circular for the AGM, not just a brief announcement or proxy solicitation. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-04-20 English
2021 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2021 ANNUAL REPORT' and contains detailed sections typical of an annual report, including Corporate Information, Business and Financial Highlights, Management Discussion and Analysis, Directors and Senior Management, Corporate Governance Report, Financial Summary, Environmental, Social and Governance Report, Independent Auditor’s Report, and Consolidated Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data, management analysis, and auditor's report confirms it is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 March 2022. It details movements in authorized and issued shares, share options, and other share capital information. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables on share capital and share options. The document is a regulatory submission related to share capital movements and does not contain financial statements or management discussion. It is not an annual or interim report, earnings release, or investor presentation. It is a regulatory filing specific to share capital movements and share options under exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-04-06 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021' and contains detailed financial highlights, business highlights, clinical trial updates, and management discussion and analysis for the full fiscal year ended December 31, 2021. It includes audited consolidated results and comparative figures for the year, which are typical components of an Annual Report. The length of the document (15,000 characters) and the presence of substantive financial data and business analysis confirm it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-03-25 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Immunotech Biopharm Ltd regarding the scheduling of a board meeting to consider and approve the annual results for the year ended 31 December 2021. It does not contain the actual annual report or financial data but merely informs about the date of the board meeting where the annual results will be reviewed and published. The document length is only 1400 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2022-03-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.